Entrada Therapeutics (TRDA) FCF Margin (2023 - 2026)

Entrada Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 4765.14% for Q1 2026.

• In Q1 2026, FCF Margin fell 457227.0% year-over-year to 4765.14%; the TTM figure through Mar 2026 stood at 2293.43% (down 226126.0% YoY), while the FY2025 annual figure was 509.63%, down 48965.0% from the prior year.
• FCF Margin was 4765.14% for Q1 2026 at Entrada Therapeutics, down from 2559.2% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 798.62% in Q1 2023 to a low of 4765.14% in Q1 2026.
• Historically, FCF Margin has averaged 799.29% across 4 years, with a median of 114.68% in 2024.
• The sharpest annual moves came in 2024 and 2026: FCF Margin surged 24246 bps in 2024, then plunged 457227 bps in 2026.
• A 4-year view of FCF Margin shows it stood at 9.37% in 2023, then tumbled by 816 bps to 85.85% in 2024, then slumped by 2881 bps to 2559.2% in 2025, then tumbled by 86 bps to 4765.14% in 2026.
• The last three FCF Margin figures came in at 4765.14% (Q1 2026), 2559.2% (Q4 2025), and 1754.21% (Q3 2025), per Business Quant data.